APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sustained Release Injectables

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Sustained Release Injectables Market Outlook and Growth Opportunities 2026

20 December 2025219 pages

Choose your research edition.

Industry ResearchSustained Release Injectables Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Sustained Release Injectables Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Sustained Release Injectables Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sustained Release Injectables Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Sustained Release Injectables Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Sustained Release Injectables market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Sustained Release Injectables is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sustained Release Injectables is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sustained Release Injectables is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Sustained Release Injectables market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Sustained Release Injectables market include Sanofi, Novartis, Merck, Luye Pharma Group, Roche, Livzon Pharm, Eli Lilly, AstraZeneca and Xbrane Biopharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Sustained Release Injectables market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sustained Release Injectables and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sustained Release Injectables revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Sustained Release Injectables market.

Sustained Release Injectables Segment by Company

Sanofi

Novartis

Merck

Luye Pharma Group

Roche

Livzon Pharm

Eli Lilly

AstraZeneca

Xbrane Biopharma

Taiwan Liposome Company (TLC)

Recipharm AB

PhaseBio Pharmaceuticals

Pacira

OctoPlus

Oakwood Laboratories/PharmaSophia

NanOlogy

Janssen

Ipsen

InnoCore Pharmaceuticals

Enzon

Durect

Critical Pharmaceuticals

Camurus

Biomarin

Avadel

Aurobindo

Ascendis Pharma

AntriaBio

Amylin Pharmaceuticals

Alkermes

Sustained Release Injectables Segment by Type

Gels

Microparticles

Implants

Sustained Release Injectables Segment by Application

Oncology

CNS

Acromegaly

Ophthalmology

Diabetes

Reproductive Health

Rheumatology

Leukemia

Others

Sustained Release Injectables Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Sustained Release Injectables status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Sustained Release Injectables key companies, revenue, market share, and recent developments.

3. To split the Sustained Release Injectables breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Sustained Release Injectables market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Sustained Release Injectables significant trends, drivers, influence factors in global and regions.

6. To analyze Sustained Release Injectables competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Injectables.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sustained Release Injectables industry.

Chapter 3: Detailed analysis of Sustained Release Injectables company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Sustained Release Injectables in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Sustained Release Injectables in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Sustained Release Injectables Industry Trends Table 2. Sustained Release Injectables Industry Drivers Table 3. Sustained Release Injectables Industry Opportunities and Challenges Table 4. Sustained Release Injectables Industry Restraints Table 5. Global Sustained Release Injectables Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Sustained Release Injectables Revenue Share by Company (2021-2026) Table 7. Global Sustained Release Injectables Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Sustained Release Injectables Key Company Manufacturing Base & Headquarters Table 9. Global Sustained Release Injectables Company, Product Type & Application Table 10. Global Sustained Release Injectables Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Sustained Release Injectables by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Gels Table 15. Significant Companies of Microparticles Table 16. Significant Companies of Implants Table 17. Global Sustained Release Injectables Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Sustained Release Injectables Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Sustained Release Injectables Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Sustained Release Injectables Sales Value Share by Type (2021-2026) Table 21. Global Sustained Release Injectables Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Oncology Table 23. Significant Companies of CNS Table 24. Significant Companies of Acromegaly Table 25. Significant Companies of Ophthalmology Table 26. Significant Companies of Diabetes Table 27. Significant Companies of Reproductive Health Table 28. Significant Companies of Rheumatology Table 29. Significant Companies of Leukemia Table 30. Significant Companies of Others Table 31. Global Sustained Release Injectables Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Sustained Release Injectables Sales Value by Application (2021-2026) & (US$ Million) Table 33. Global Sustained Release Injectables Sales Value by Application (2027-2032) & (US$ Million) Table 34. Global Sustained Release Injectables Sales Value Share by Application (2021-2026) Table 35. Global Sustained Release Injectables Sales Value Share by Application (2027-2032) Table 36. Global Sustained Release Injectables Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Sustained Release Injectables Sales Value by Region (2021-2026) & (US$ Million) Table 38. Global Sustained Release Injectables Sales Value Share by Region (2021-2026) Table 39. Global Sustained Release Injectables Sales Value by Region (2027-2032) & (US$ Million) Table 40. Global Sustained Release Injectables Sales Value Share by Region (2027-2032) Table 41. Global Sustained Release Injectables Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Sustained Release Injectables Sales Value by Country (2021-2026) & (US$ Million) Table 43. Global Sustained Release Injectables Sales Value Market Share by Country (2021-2026) Table 44. Global Sustained Release Injectables Sales Value by Country (2027-2032) & (US$ Million) Table 45. Global Sustained Release Injectables Sales Value Market Share by Country (2027-2032) Table 46. Sanofi Company Information Table 47. Sanofi Business Overview Table 48. Sanofi Sustained Release Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Sanofi Sustained Release Injectables Product Portfolio Table 50. Sanofi Recent Development Table 51. Novartis Company Information Table 52. Novartis Business Overview Table 53. Novartis Sustained Release Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Novartis Sustained Release Injectables Product Portfolio Table 55. Novartis Recent Development Table 56. Merck Company Information Table 57. Merck Business Overview Table 58. Merck Sustained Release Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Merck Sustained Release Injectables Product Portfolio Table 60. Merck Recent Development Table 61. Luye Pharma Group Company Information Table 62. Luye Pharma Group Business Overview Table 63. Luye Pharma Group Sustained Release Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Luye Pharma Group Sustained Release Injectables Product Portfolio Table 65. Luye Pharma Group Recent Development Table 66. Roche Company Information Table 67. Roche Business Overview Table 68. Roche Sustained Release Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Roche Sustained Release Injectables Product Portfolio Table 70. Roche Recent Development Table 71. Livzon Pharm Company Information Table 72. Livzon Pharm Business Overview Table 73. Livzon Pharm Sustained Release Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Livzon Pharm Sustained Release Injectables Product Portfolio Table 75. Livzon Pharm Recent Development Table 76. Eli Lilly Company Information Table 77. Eli Lilly Business Overview Table 78. Eli Lilly Sustained Release Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Eli Lilly Sustained Release Injectables Product Portfolio Table 80. Eli Lilly Recent Development Table 81. AstraZeneca Company Information Table 82. AstraZeneca Business Overview Table 83. AstraZeneca Sustained Release Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. AstraZeneca Sustained Release Injectables Product Portfolio Table 85. AstraZeneca Recent Development Table 86. Xbrane Biopharma Company Information Table 87. Xbrane Biopharma Business Overview Table 88. Xbrane Biopharma Sustained Release Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Xbrane Biopharma Sustained Release Injectables Product Portfolio Table 90. Xbrane Biopharma Recent Development Table 91. Taiwan Liposome Company (TLC) Company Information Table 92. Taiwan Liposome Company (TLC) Business Overview Table 93. Taiwan Liposome Company (TLC) Sustained Release Injectables Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio Table 95. Taiwan Liposome Company (TLC) Recent Development Table 96. Recipharm AB Company Information Table 97. Recipharm AB Business Overview Table 98. Recipharm AB Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Recipharm AB Sustained Release Injectables Product Portfolio Table 100. Recipharm AB Recent Development Table 101. PhaseBio Pharmaceuticals Company Information Table 102. PhaseBio Pharmaceuticals Business Overview Table 103. PhaseBio Pharmaceuticals Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio Table 105. PhaseBio Pharmaceuticals Recent Development Table 106. Pacira Company Information Table 107. Pacira Business Overview Table 108. Pacira Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Pacira Sustained Release Injectables Product Portfolio Table 110. Pacira Recent Development Table 111. OctoPlus Company Information Table 112. OctoPlus Business Overview Table 113. OctoPlus Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. OctoPlus Sustained Release Injectables Product Portfolio Table 115. OctoPlus Recent Development Table 116. Oakwood Laboratories/PharmaSophia Company Information Table 117. Oakwood Laboratories/PharmaSophia Business Overview Table 118. Oakwood Laboratories/PharmaSophia Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio Table 120. Oakwood Laboratories/PharmaSophia Recent Development Table 121. NanOlogy Company Information Table 122. NanOlogy Business Overview Table 123. NanOlogy Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. NanOlogy Sustained Release Injectables Product Portfolio Table 125. NanOlogy Recent Development Table 126. Janssen Company Information Table 127. Janssen Business Overview Table 128. Janssen Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Janssen Sustained Release Injectables Product Portfolio Table 130. Janssen Recent Development Table 131. Ipsen Company Information Table 132. Ipsen Business Overview Table 133. Ipsen Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Ipsen Sustained Release Injectables Product Portfolio Table 135. Ipsen Recent Development Table 136. InnoCore Pharmaceuticals Company Information Table 137. InnoCore Pharmaceuticals Business Overview Table 138. InnoCore Pharmaceuticals Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio Table 140. InnoCore Pharmaceuticals Recent Development Table 141. Enzon Company Information Table 142. Enzon Business Overview Table 143. Enzon Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Enzon Sustained Release Injectables Product Portfolio Table 145. Enzon Recent Development Table 146. Durect Company Information Table 147. Durect Business Overview Table 148. Durect Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. Durect Sustained Release Injectables Product Portfolio Table 150. Durect Recent Development Table 151. Critical Pharmaceuticals Company Information Table 152. Critical Pharmaceuticals Business Overview Table 153. Critical Pharmaceuticals Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 154. Critical Pharmaceuticals Sustained Release Injectables Product Portfolio Table 155. Critical Pharmaceuticals Recent Development Table 156. Camurus Company Information Table 157. Camurus Business Overview Table 158. Camurus Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 159. Camurus Sustained Release Injectables Product Portfolio Table 160. Camurus Recent Development Table 161. Biomarin Company Information Table 162. Biomarin Business Overview Table 163. Biomarin Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 164. Biomarin Sustained Release Injectables Product Portfolio Table 165. Biomarin Recent Development Table 166. Avadel Company Information Table 167. Avadel Business Overview Table 168. Avadel Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 169. Avadel Sustained Release Injectables Product Portfolio Table 170. Avadel Recent Development Table 171. Aurobindo Company Information Table 172. Aurobindo Business Overview Table 173. Aurobindo Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 174. Aurobindo Sustained Release Injectables Product Portfolio Table 175. Aurobindo Recent Development Table 176. Ascendis Pharma Company Information Table 177. Ascendis Pharma Business Overview Table 178. Ascendis Pharma Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 179. Ascendis Pharma Sustained Release Injectables Product Portfolio Table 180. Ascendis Pharma Recent Development Table 181. AntriaBio Company Information Table 182. AntriaBio Business Overview Table 183. AntriaBio Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 184. AntriaBio Sustained Release Injectables Product Portfolio Table 185. AntriaBio Recent Development Table 186. Amylin Pharmaceuticals Company Information Table 187. Amylin Pharmaceuticals Business Overview Table 188. Amylin Pharmaceuticals Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 189. Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio Table 190. Amylin Pharmaceuticals Recent Development Table 191. Alkermes Company Information Table 192. Alkermes Business Overview Table 193. Alkermes Sustained Release Injectables Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 194. Alkermes Sustained Release Injectables Product Portfolio Table 195. Alkermes Recent Development Table 196. Research Programs/Design for This Report Table 197. Authors List of This Report Table 198. Secondary Sources Table 199. Primary Sources List of Figures Figure 1. Sustained Release Injectables Product Image Figure 2. Global Sustained Release Injectables Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sustained Release Injectables Market Size (2021-2032) & (US$ Million) Figure 4. Global Sustained Release Injectables Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Gels Image Figure 8. Microparticles Image Figure 9. Implants Image Figure 10. Global Sustained Release Injectables Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Sustained Release Injectables Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Sustained Release Injectables Sales Value Share by Type (2021-2032) Figure 13. Oncology Image Figure 14. CNS Image Figure 15. Acromegaly Image Figure 16. Ophthalmology Image Figure 17. Diabetes Image Figure 18. Reproductive Health Image Figure 19. Rheumatology Image Figure 20. Leukemia Image Figure 21. Others Image Figure 22. Global Sustained Release Injectables Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Sustained Release Injectables Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Sustained Release Injectables Sales Value Share by Application (2021-2032) Figure 25. Global Sustained Release Injectables Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 26. Global Sustained Release Injectables Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 27. North America Sustained Release Injectables Sales Value (2021-2032) & (US$ Million) Figure 28. North America Sustained Release Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Europe Sustained Release Injectables Sales Value (2021-2032) & (US$ Million) Figure 30. Europe Sustained Release Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Asia-Pacific Sustained Release Injectables Sales Value (2021-2032) & (US$ Million) Figure 32. Asia-Pacific Sustained Release Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 33. South America Sustained Release Injectables Sales Value (2021-2032) & (US$ Million) Figure 34. South America Sustained Release Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Middle East & Africa Sustained Release Injectables Sales Value (2021-2032) & (US$ Million) Figure 36. Middle East & Africa Sustained Release Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 37. USA Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. USA Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. USA Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Canada Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Canada Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Canada Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Mexico Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Mexico Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Mexico Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Germany Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Germany Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Germany Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. France Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. France Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. France Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. U.K. Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. U.K. Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. U.K. Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Italy Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Italy Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Italy Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Spain Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Spain Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Spain Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Russia Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Russia Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Russia Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Netherlands Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Netherlands Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Netherlands Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Nordic Countries Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Nordic Countries Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Nordic Countries Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. China Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. China Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. China Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Japan Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Japan Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Japan Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. South Korea Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. South Korea Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. South Korea Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. India Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. India Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. India Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Australia Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Australia Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Australia Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Southeast Asia Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Southeast Asia Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Southeast Asia Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Brazil Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Brazil Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Brazil Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Argentina Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Argentina Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Argentina Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Chile Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Chile Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Chile Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Colombia Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Colombia Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Colombia Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Peru Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Peru Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Peru Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Saudi Arabia Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Israel Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Israel Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Israel Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. UAE Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. UAE Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. UAE Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Turkey Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Turkey Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Turkey Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Iran Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Iran Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Iran Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Egypt Sustained Release Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Egypt Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Egypt Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Years Considered Figure 122. Research Process Figure 123. Key Executives Interviewed

Scope & coverage.

Types
  • Gels
  • Microparticles
  • Implants
Applications
  • Oncology
  • CNS
  • Acromegaly
  • Ophthalmology
  • Diabetes
  • Reproductive Health
  • Rheumatology
  • Leukemia
  • Others
Companies covered
  • Sanofi
  • Novartis
  • Merck
  • Luye Pharma Group
  • Roche
  • Livzon Pharm
  • Eli Lilly
  • AstraZeneca
  • Xbrane Biopharma
  • Taiwan Liposome Company (TLC)
  • Recipharm AB
  • PhaseBio Pharmaceuticals
  • Pacira
  • OctoPlus
  • Oakwood Laboratories/PharmaSophia
  • NanOlogy
  • Janssen
  • Ipsen
  • InnoCore Pharmaceuticals
  • Enzon
  • Durect
  • Critical Pharmaceuticals
  • Camurus
  • Biomarin
  • Avadel
  • Aurobindo
  • Ascendis Pharma
  • AntriaBio
  • Amylin Pharmaceuticals
  • Alkermes

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Sustained Release Injectables Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Sustained Release Injectables Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Sustained Release Injectables Market Dynamics
  1. 2.1 Sustained Release Injectables Industry Trends
  2. 2.2 Sustained Release Injectables Industry Drivers
  3. 2.3 Sustained Release Injectables Industry Opportunities and Challenges
  4. 2.4 Sustained Release Injectables Industry Restraints
3 Sustained Release Injectables Market by Company
  1. 3.1 Global Sustained Release Injectables Company Revenue Ranking in 2025
  2. 3.2 Global Sustained Release Injectables Revenue by Company (2021-2026)
  3. 3.3 Global Sustained Release Injectables Company Ranking (2024-2026)
  4. 3.4 Global Sustained Release Injectables Company Manufacturing Base and Headquarters
  5. 3.5 Global Sustained Release Injectables Company Product Type and Application
  6. 3.6 Global Sustained Release Injectables Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Sustained Release Injectables Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Sustained Release Injectables Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Sustained Release Injectables Market by Type
  1. 4.1 Sustained Release Injectables Type Introduction
  2. 4.1.1 Gels
  3. 4.1.2 Microparticles
  4. 4.1.3 Implants
  5. 4.2 Global Sustained Release Injectables Sales Value by Type
  6. 4.2.1 Global Sustained Release Injectables Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Sustained Release Injectables Sales Value by Type (2021-2032)
  8. 4.2.3 Global Sustained Release Injectables Sales Value Share by Type (2021-2032)
5 Sustained Release Injectables Market by Application
  1. 5.1 Sustained Release Injectables Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 CNS
  4. 5.1.3 Acromegaly
  5. 5.1.4 Ophthalmology
  6. 5.1.5 Diabetes
  7. 5.1.6 Reproductive Health
  8. 5.1.7 Rheumatology
  9. 5.1.8 Leukemia
  10. 5.1.9 Others
  11. 5.2 Global Sustained Release Injectables Sales Value by Application
  12. 5.2.1 Global Sustained Release Injectables Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.2.2 Global Sustained Release Injectables Sales Value by Application (2021-2032)
  14. 5.2.3 Global Sustained Release Injectables Sales Value Share by Application (2021-2032)
6 Sustained Release Injectables Regional Value Analysis
  1. 6.1 Global Sustained Release Injectables Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sustained Release Injectables Sales Value by Region (2021-2032)
  3. 6.2.1 Global Sustained Release Injectables Sales Value by Region: 2021-2026
  4. 6.2.2 Global Sustained Release Injectables Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Sustained Release Injectables Sales Value (2021-2032)
  7. 6.3.2 North America Sustained Release Injectables Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Sustained Release Injectables Sales Value (2021-2032)
  10. 6.4.2 Europe Sustained Release Injectables Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Sustained Release Injectables Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Sustained Release Injectables Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Sustained Release Injectables Sales Value (2021-2032)
  16. 6.6.2 South America Sustained Release Injectables Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Sustained Release Injectables Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Sustained Release Injectables Sales Value Share by Country, 2025 VS 2032
7 Sustained Release Injectables Country-level Value Analysis
  1. 7.1 Global Sustained Release Injectables Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Sustained Release Injectables Sales Value by Country (2021-2032)
  3. 7.2.1 Global Sustained Release Injectables Sales Value by Country (2021-2026)
  4. 7.2.2 Global Sustained Release Injectables Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Sustained Release Injectables Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Sustained Release Injectables Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Sustained Release Injectables Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Sustained Release Injectables Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Sustained Release Injectables Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Sustained Release Injectables Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Luye Pharma Group
  20. 8.4.1 Luye Pharma Group Company Information
  21. 8.4.2 Luye Pharma Group Business Overview
  22. 8.4.3 Luye Pharma Group Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Luye Pharma Group Sustained Release Injectables Product Portfolio
  24. 8.4.5 Luye Pharma Group Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Sustained Release Injectables Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Livzon Pharm
  32. 8.6.1 Livzon Pharm Company Information
  33. 8.6.2 Livzon Pharm Business Overview
  34. 8.6.3 Livzon Pharm Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Livzon Pharm Sustained Release Injectables Product Portfolio
  36. 8.6.5 Livzon Pharm Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Sustained Release Injectables Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Sustained Release Injectables Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
  49. 8.9 Xbrane Biopharma
  50. 8.9.1 Xbrane Biopharma Company Information
  51. 8.9.2 Xbrane Biopharma Business Overview
  52. 8.9.3 Xbrane Biopharma Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Xbrane Biopharma Sustained Release Injectables Product Portfolio
  54. 8.9.5 Xbrane Biopharma Recent Developments
  55. 8.10 Taiwan Liposome Company (TLC)
  56. 8.10.1 Taiwan Liposome Company (TLC) Company Information
  57. 8.10.2 Taiwan Liposome Company (TLC) Business Overview
  58. 8.10.3 Taiwan Liposome Company (TLC) Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio
  60. 8.10.5 Taiwan Liposome Company (TLC) Recent Developments
  61. 8.11 Recipharm AB
  62. 8.11.1 Recipharm AB Company Information
  63. 8.11.2 Recipharm AB Business Overview
  64. 8.11.3 Recipharm AB Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Recipharm AB Sustained Release Injectables Product Portfolio
  66. 8.11.5 Recipharm AB Recent Developments
  67. 8.12 PhaseBio Pharmaceuticals
  68. 8.12.1 PhaseBio Pharmaceuticals Company Information
  69. 8.12.2 PhaseBio Pharmaceuticals Business Overview
  70. 8.12.3 PhaseBio Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  71. 8.12.4 PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio
  72. 8.12.5 PhaseBio Pharmaceuticals Recent Developments
  73. 8.13 Pacira
  74. 8.13.1 Pacira Company Information
  75. 8.13.2 Pacira Business Overview
  76. 8.13.3 Pacira Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pacira Sustained Release Injectables Product Portfolio
  78. 8.13.5 Pacira Recent Developments
  79. 8.14 OctoPlus
  80. 8.14.1 OctoPlus Company Information
  81. 8.14.2 OctoPlus Business Overview
  82. 8.14.3 OctoPlus Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  83. 8.14.4 OctoPlus Sustained Release Injectables Product Portfolio
  84. 8.14.5 OctoPlus Recent Developments
  85. 8.15 Oakwood Laboratories/PharmaSophia
  86. 8.15.1 Oakwood Laboratories/PharmaSophia Company Information
  87. 8.15.2 Oakwood Laboratories/PharmaSophia Business Overview
  88. 8.15.3 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio
  90. 8.15.5 Oakwood Laboratories/PharmaSophia Recent Developments
  91. 8.16 NanOlogy
  92. 8.16.1 NanOlogy Company Information
  93. 8.16.2 NanOlogy Business Overview
  94. 8.16.3 NanOlogy Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  95. 8.16.4 NanOlogy Sustained Release Injectables Product Portfolio
  96. 8.16.5 NanOlogy Recent Developments
  97. 8.17 Janssen
  98. 8.17.1 Janssen Company Information
  99. 8.17.2 Janssen Business Overview
  100. 8.17.3 Janssen Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Janssen Sustained Release Injectables Product Portfolio
  102. 8.17.5 Janssen Recent Developments
  103. 8.18 Ipsen
  104. 8.18.1 Ipsen Company Information
  105. 8.18.2 Ipsen Business Overview
  106. 8.18.3 Ipsen Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Ipsen Sustained Release Injectables Product Portfolio
  108. 8.18.5 Ipsen Recent Developments
  109. 8.19 InnoCore Pharmaceuticals
  110. 8.19.1 InnoCore Pharmaceuticals Company Information
  111. 8.19.2 InnoCore Pharmaceuticals Business Overview
  112. 8.19.3 InnoCore Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  113. 8.19.4 InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio
  114. 8.19.5 InnoCore Pharmaceuticals Recent Developments
  115. 8.20 Enzon
  116. 8.20.1 Enzon Company Information
  117. 8.20.2 Enzon Business Overview
  118. 8.20.3 Enzon Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Enzon Sustained Release Injectables Product Portfolio
  120. 8.20.5 Enzon Recent Developments
  121. 8.21 Durect
  122. 8.21.1 Durect Company Information
  123. 8.21.2 Durect Business Overview
  124. 8.21.3 Durect Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Durect Sustained Release Injectables Product Portfolio
  126. 8.21.5 Durect Recent Developments
  127. 8.22 Critical Pharmaceuticals
  128. 8.22.1 Critical Pharmaceuticals Company Information
  129. 8.22.2 Critical Pharmaceuticals Business Overview
  130. 8.22.3 Critical Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Critical Pharmaceuticals Sustained Release Injectables Product Portfolio
  132. 8.22.5 Critical Pharmaceuticals Recent Developments
  133. 8.23 Camurus
  134. 8.23.1 Camurus Company Information
  135. 8.23.2 Camurus Business Overview
  136. 8.23.3 Camurus Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Camurus Sustained Release Injectables Product Portfolio
  138. 8.23.5 Camurus Recent Developments
  139. 8.24 Biomarin
  140. 8.24.1 Biomarin Company Information
  141. 8.24.2 Biomarin Business Overview
  142. 8.24.3 Biomarin Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Biomarin Sustained Release Injectables Product Portfolio
  144. 8.24.5 Biomarin Recent Developments
  145. 8.25 Avadel
  146. 8.25.1 Avadel Company Information
  147. 8.25.2 Avadel Business Overview
  148. 8.25.3 Avadel Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Avadel Sustained Release Injectables Product Portfolio
  150. 8.25.5 Avadel Recent Developments
  151. 8.26 Aurobindo
  152. 8.26.1 Aurobindo Company Information
  153. 8.26.2 Aurobindo Business Overview
  154. 8.26.3 Aurobindo Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Aurobindo Sustained Release Injectables Product Portfolio
  156. 8.26.5 Aurobindo Recent Developments
  157. 8.27 Ascendis Pharma
  158. 8.27.1 Ascendis Pharma Company Information
  159. 8.27.2 Ascendis Pharma Business Overview
  160. 8.27.3 Ascendis Pharma Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Ascendis Pharma Sustained Release Injectables Product Portfolio
  162. 8.27.5 Ascendis Pharma Recent Developments
  163. 8.28 AntriaBio
  164. 8.28.1 AntriaBio Company Information
  165. 8.28.2 AntriaBio Business Overview
  166. 8.28.3 AntriaBio Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  167. 8.28.4 AntriaBio Sustained Release Injectables Product Portfolio
  168. 8.28.5 AntriaBio Recent Developments
  169. 8.29 Amylin Pharmaceuticals
  170. 8.29.1 Amylin Pharmaceuticals Company Information
  171. 8.29.2 Amylin Pharmaceuticals Business Overview
  172. 8.29.3 Amylin Pharmaceuticals Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  173. 8.29.4 Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio
  174. 8.29.5 Amylin Pharmaceuticals Recent Developments
  175. 8.30 Alkermes
  176. 8.30.1 Alkermes Company Information
  177. 8.30.2 Alkermes Business Overview
  178. 8.30.3 Alkermes Sustained Release Injectables Revenue and Gross Margin (2021-2026)
  179. 8.30.4 Alkermes Sustained Release Injectables Product Portfolio
  180. 8.30.5 Alkermes Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst